This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Underdiagnosed and Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) and Myelofibrosis (MF)

Underdiagnosed and Undertreated: A Cutting-Edge Perspective on Polycythemia Vera (PV) and Myelofibrosis (MF)

Format

Interactive Monograph

Time to Complete

45 minutes

Released

February 22, 2017

Expires

February 22, 2018
Add to Queue


Maximum Credits

0.75 / AMA PRA Category 1 Credit(s)TM
0.75 / CE for Nurses (0.30 pharmacotherapeutic contact hours)

Accredited Provider

Jointly provided by American Academy of CME, Inc. and CME Matters, Inc.

Commercial Supporter

Supported by Incyte Corporation

Program Description

One of three primary Ph-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV) is a clonal disorder characterized by unwarranted production of red blood cells. Presently, the majority of patients are diagnosed only by chance or following a thrombotic event, representing a significant lost opportunity to start treatment early in the course of the disease. Of those patients with PV, approximately 6% will progress to develop myelofibrosis (MF), another MPN that carries a significantly reduced average overall survival compared to PV. This activity utilizes a unique, visually-oriented, self-paced and animated infographic format covering the diagnosis and treatment of patients with PV and MF.

Intended Audience

The target audience for this initiative includes hematologists, oncologists, hematology/oncology nurses, emergency room physicians and nurses, or anyone in the position to diagnose and/or treat patients with PV and MF.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Identify the most common presenting characteristics of patients with PV prior to diagnosis
  • Weigh the benefits and drawbacks of aggressive front-line treatment of PV
  • Analyze the potential effectiveness and side effect profiles for second-line treatment options used in patients with PV who are either intolerant or refractory to hydroxyurea
  • Identify risk factors for progression to post-PV MF, as well as prognostic variables that may impact overall survival once progression occurs
  • Discuss the clinical effectiveness and side effect profile of approved and investigational agents used to treat MF

Conflict Of Interest Disclosure Policy

All faculty, planners and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Faculty

Ross Levine, MD
Member, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, NY

Dr. Levine has affiliations with with Cell Therapeutics Biopharma, Incyte Corporation, Novartis (Advisory Boards), Incyte Corporation and Novartis (Grant Recipient).

Michael Savona, MD
Associate Professor of Medicine
Director, Hematology Early Therapeutics Program
Vanderbilt-Ingram Cancer Center
Nashville, TN

Dr. Savona has affiliations with Amgen, Ariad, Baxalta, Celgene, Gilead, Incyte Corporation, Karyopharm, Novartis (Advisory Board), Karyopharm, Bristol-Myers Squibb (Consultant), Karyopharm (Shareholder), Astex, Sunesis, Incyte Corporation,Takeda, and TG Therapeutics (Grant Recipient).

Accredited Provider Disclosure

Cathy Pagano, CHCP, and Scott Kober, MBA, CHCP, (CME Matters LLC), and John JD Juchniewicz, MCIS, CHCP, and Natalie Kirkwood, RN, BSN, JD—Lead Nurse Planner (American Academy of CME, Inc.) have no relevant financial relationships specific to the subject matter within the past 12 months.

Credit

0.75

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Academy of CME, Inc., (Academy) and CME Matters LLC. The Academy is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Academy designates this activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit

0.75

Type

CE for Nurses

Accreditation Statement

American Academy of CME, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Designation Statement

American Academy of CME, Inc. designates this educational activity for 0.75 contact hours (0.30 pharmacotherapeutic contact hours).

Disclosure of Unlabeled Use

This activity will not review off-label or investigational information.

Disclaimer

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy, CME Matters or American Nurses Credentialing Center’s Commission on Accreditation. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

For questions about CME/CNE credit, please contact: CEServices@academycme.org.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test (achieving a passing score of 70%) and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

Privacy Policy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm

myCME privacy policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue